Evolution of Clinical Practice Guidelines: Evidence Supporting Expanded Use of Medicines
- 1 August 2006
- journal article
- research article
- Published by Mary Ann Liebert Inc in Disease Management
- Vol. 9 (4), 210-223
- https://doi.org/10.1089/dis.2006.9.210
Abstract
Previous studies have shown that the primary factor underlying increased spending on pharmaceuticals has been the rising utilization of medications, rather than increases in unit drug price. This study examined the evolution of clinical practice guidelines to assess possible reasons for the rising drug volume. Clinical practice guidelines from 1970 to the present were reviewed for the six most prevalent treatable medical conditions/risk factors listed as priority areas by the Institute of Medicine. We searched the National Guidelines Clearinghouse, PubMed and Medline databases, and Web sites of relevant national organizations for US clinical practice guidelines published through January 2005. Information pertaining to the therapeutic regimen (eg, the frequency and duration of recommended treatment, when treatment should be initiated, the patient population for whom the guideline was intended) was abstracted and entered into evidence tables. Changes in guidelines were distributed across three themes that recommended evidence-based increases in medication use, including: (1) changes in the size of the treatable population; (2) changes in the number and type of recommended pharmaceutical therapeutic options, including movement from monotherapy to combination therapy, treatment of comorbidities, and use of newer types of medicines; and (3) changes in the therapeutic regimen, including a shift from episodic care to preventive and chronic care. Many of these changes point to an important, but not often noticed, addition of secondary prevention of disease effects to the objectives of medical care. These trends are likely to continue with important economic, clinical, and policy ramifications. (Disease Management 2006;9:210–223)Keywords
This publication has 34 references indexed in Scilit:
- Prognosis of Atrial Fibrillation in Congestive Heart FailureCirculation, 2004
- Early use of glycoprotein IIb/IIIa inhibitors in non–ST-elevation acute myocardial infarctionJournal of the American College of Cardiology, 2003
- The Prevention or Delay of Type 2 DiabetesDiabetes Care, 2002
- Geographic Variation In The Use Of Medications: Is Uniformity Good News Or Bad?Health Affairs, 2002
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressureArchives of Internal Medicine, 1997
- The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V)Archives of Internal Medicine, 1993
- The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood PressureArchives of Internal Medicine, 1988
- Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert PanelArchives of Internal Medicine, 1988
- The 1984 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood PressureArchives of Internal Medicine, 1984